Skip to main content
Log in

Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Effort-related motivational symptoms, such as anergia, psychomotor retardation, and fatigue, are an important aspect of depression and other disorders. Motivational symptoms are resistant to some treatments, including serotonin transport (SERT) inhibitors.

Objectives

Tests of effort-based choice using operant behavior tasks (e.g., concurrent lever pressing/ chow feeding tasks) can be used as animal models of motivational symptoms. Tests of effort-related choice allow animals to choose between high-effort actions that lead to more highly valued rewards vs. low-effort alternatives that lead to less valued rewards (i.e., less preferred or lower magnitude). Rats treated with the vesicular monoamine transport inhibitor tetrabenazine, or the cytokine interleukin-1β (IL-1β), which are associated with depressive symptoms in humans, can alter effort-related choice, reducing selection of the high effort alternative (lever pressing) while increasing intake of freely available chow.

Methods

The present studies focused upon the ability of lisdexamfetamine (LDX) to increase exertion of effort in rats responding on effort-based choice tasks under several different conditions.

Results

LDX attenuated the shift from fixed ratio 5 lever pressing to chow intake induced by tetrabenazine and IL-1β. In contrast, the SERT inhibitor s-citalopram failed to reverse the effects of tetrabenazine. When given in combination with tetrabenazine+s-citalopram, LDX significantly increased lever pressing output compared to tetrabenaine+citalopram alone. LDX also increased work output in rats responding on a progressive ratio/chow feeding choice task.

Conclusions

LDX can increase work output in rats responding on effort-based choice tasks, which may have implications for understanding the neurochemistry of motivational symptoms in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, Prieto D, Palomo T (2006) Negative signs and symptoms secondary to antipsychotics: a double-blind randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163:488–493

    Article  PubMed  Google Scholar 

  • Bardgett ME, Depenbrock M, Downs N, Points M, Green L (2009) Dopamine modulates effort-based decision making in rats. Behav Neurosci 123:242–251

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Becker PM, Schwartz JR, Feldman NT, Hughes RJ (2004) Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology (Berlin) 171:133–139

    Article  CAS  Google Scholar 

  • Beeler JA, Frazier CR, Zhuang X (2012) Putting desire on a budget: dopamine and energy expenditure, reconciling reward and resources. Front Integr Neurosci 6:49

    Article  PubMed Central  PubMed  Google Scholar 

  • Beeler JA, Faust RP, Turkson S, Ye H, Zhuang X (2015) Low dopamine D2 receptor increases vulnerability to obesity via reduced physical activity not increased appetitive motivation. Biol Psychiat. doi: 10.1016/j.biopsych.2015.07.009. [Epub ahead of print]

  • Cagniard B, Balsam PD, Brunner D, Zhuang X (2006) Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 31:1362–1370

    Article  CAS  PubMed  Google Scholar 

  • Caligiuri MP, Gentili V, Eberson S, Kelsoe J, Rapaport M, Gillin JC (2003) A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. J Affect Disord 77:135–141

    Article  PubMed  Google Scholar 

  • Candy M, Jones L, Williams R, Tookman A, King M (2008) Psychostimulants for depression. Cochrane Database Syst Rev 2:CD006722

    PubMed  Google Scholar 

  • Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34:1487–1504

    Article  PubMed  Google Scholar 

  • Chong TT, Bonnelle V, Manohar S, Veromann KR, Muhammed K, Tofaris GK, Hu M, Husain M (2015) Dopamine enhances willingness to exert effort for reward in Parkinson’s disease. Cortex 69:40–46

    Article  PubMed Central  PubMed  Google Scholar 

  • Cooper JA, Tucker VL, Papakostas GI (2014) Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol 28:118–124

    Article  CAS  PubMed  Google Scholar 

  • Cousins MS, Atherton A, Turner L, Salamone JD (1996) Nucleus accumbens dopamine depletions alter relative response allocation in a T-maze cost/benefit task. Behav Brain Res 74:189–197

    Article  CAS  PubMed  Google Scholar 

  • Dantzer R (2009) Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 29:247–264

    Article  PubMed Central  PubMed  Google Scholar 

  • Dantzer R, Meagher MW, Cleeland CS (2012) Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol 9:414–426

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Demyttenaere K, De Fruyt J, Stahl SM (2005) The many faces of fatigue in major depressive disorder. J Neuropsychopharmacol 8:93–105

    Article  Google Scholar 

  • Devos D, Moreau C, Delval A, Dujardin K, Defebvre L, Bordet R (2013) Methylphenidate: a treatment for Parkinson’s disease? CNS Drugs 27:1–14

    Article  CAS  PubMed  Google Scholar 

  • Fava M, Ball S, Nelson JC, Sparks J, Konechnik T, Classi P, Dube S, Thase ME (2014) Clinical relevance of fatigue as a residual symptom in major depressive disorder. Depress Anxiety 31(3):250–257

    Article  PubMed  Google Scholar 

  • FDA News Release (2015) FDA expands uses of Vyvanse to treat binge-eating disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm

  • Felger JC, Miller AH (2012) Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 33(3):315–327

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Felger JC, Hernandez CR, Miller AH (2015) Levodopa reverses cytokine-induced reductions in striatal dopamine release. Int J Neuropsychopharmacol 18(4)

  • Floresco SB (2015) The nucleus accumbens: an interface between cognition, emotion, and action. Annu Rev Psychol 66:25–52

    Article  PubMed  Google Scholar 

  • Floresco SB, Tse MT, Ghods-Sharifi S (2008) Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharmacology 33:1966–1979

    Article  CAS  PubMed  Google Scholar 

  • Frank S (2009) Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 9:62

    Article  PubMed Central  PubMed  Google Scholar 

  • Frank S (2010) Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 6:657–665

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, Marsh L, Nail L, Shulman L, Taylor CB, Working Group on Fatigue in Parkinson’s Disease (2007) Fatigue in Parkinson’s disease: a review. Mov Disorder 22:297–308

    Article  Google Scholar 

  • Green TR (1997) Bupropion for SSRI-induced fatigue. J Clin Psychiatry 58:174

    Article  CAS  PubMed  Google Scholar 

  • Guay DR (2010) Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 8:331–373

    Article  CAS  PubMed  Google Scholar 

  • Hosking JG, Floresco SB, Winstanley CA (2015) Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: a comparison of two rodent cost/benefit decision-making tasks. Neuropsychopharmacology 40:1005–1015

    Article  CAS  PubMed  Google Scholar 

  • Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A (2004) Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29:566–579

    Article  CAS  PubMed  Google Scholar 

  • Kegeles LD, Abi-Darghman A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231–239

    Article  CAS  PubMed  Google Scholar 

  • Kerr CW, Drake J, Milch RA, Brazeau DA, Skretny JA, Crazeau GA, Donnelly JP (2012) Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 42:68–77

    Article  Google Scholar 

  • Keppel G (1991) Design and analysis: a researcher’s handbook, 3rd edn. Prentice-Hall, Englewood Cliffs, NJ

    Google Scholar 

  • Lasser RA, Dirks B, Nasrallah H, Kirsch C, Gao J, Pucci ML, Knesevich MA, Lindsenmayer JP (2013) Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharamcology 38:2140–2149

    Article  CAS  Google Scholar 

  • Mai B, Sommer S, Hauber W (2012) Motivational states influence effort-based decision making in rats: the role of dopamine in the nucleus accumbens. Cogn. Affect. Behav. Neurosci 12:74–84

  • Merali Z, Brennan K, Brau P, Anisman H (2003) Dissociating anorexia and anhedonia elicited by interleukin-1beta: anti-depressant and gender effects on responding for “free chow” and “earned” sucrose intake. Psychopharmacology (Berl) 165(4):413–418

    CAS  Google Scholar 

  • Miller AH (2009) Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immunity 23:149–158

    Article  CAS  Google Scholar 

  • Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, Müller CE, Salamone JD (2009) The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology (Berl) 204:103–112

    Article  CAS  Google Scholar 

  • Najib J (2009) The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 31:142–176

    Article  CAS  PubMed  Google Scholar 

  • Nunes EJ, Randall PA, Hart EE, Freeland C, Yohn SE, Baqi Y, Müller CE, López-Cruz L, Correa M, Salamone JD (2013a) Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 33:19120–19130

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Nunes EJ, Randall PA, Podurgiel S, Correa M, Salamone JD (2013b) Nucleus accumbens neurotransmission and effort-related choice behavior in food motivation: effects of drugs acting on dopamine, adenosine, and muscarinic acetylcholine receptors. Neurosci Biobehav Rev 37(9 Pt A):2015–2025

    Article  CAS  PubMed  Google Scholar 

  • Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, Baqi Y, Müller CE, Correa M, Salamone JD (2014) Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology (Berl) 231:727–773

    Article  CAS  Google Scholar 

  • Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, Carrasco JL, Stahl S (2007) The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 21:461–471

    Article  CAS  PubMed  Google Scholar 

  • Padala PR, Padala KP, Monga V, Ramirez DA, Sullivan DH (2012) Reversal of SSRI associated apathy syndrome by discontinuation of therapy. Ann Pharmacother 46:e8

    Article  PubMed  Google Scholar 

  • Pae CU, Lim HK, Han C, Patkar AA, Steffens DC, Masand PS, Lee C (2007) Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Rev Neurother 7:1251–1263

    Article  CAS  PubMed  Google Scholar 

  • Papakostas GI, Nutt DJ, Hallet LA, Tucker VL, Krishen A, Fava M (2006) Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 15:1350–1355

    Article  Google Scholar 

  • Pardo M, Lopez-Cruz L, Valverde O, Ledent C, Baqi Y, Müller CE, Salamone JD, Correa M (2012) Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice. Neuropharmacology 62:2068–2077

    Article  CAS  PubMed  Google Scholar 

  • Pardo M, Lopez-Cruz L, Miguel NS, Salamone JD, Correa M (2015) Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists. Psychopharmacology (Berl) 232:2377–2391

    Article  CAS  Google Scholar 

  • Randall PA, Lee CA, Nunes EJ, Yohn SE, Nowak V, Khan B, Shah P, Pandit S, Vemuri VK, Makriyannis A, Baqi Y, Müller CE, Correa M, Salamone JD (2014) The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. PLoS One 9(6):e99320

    Article  PubMed Central  PubMed  Google Scholar 

  • Randall PA, Lee CA, Podurgiel SJ, Hart E, Yohn SE, Jones M, Rowland M, López-Cruz L, Correa M, Salamone JD (2015) Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort related motivational symptoms. Int J Neuropsychopharmacol 18(2):1–11. doi:10.1093/ijnp/pyu017

    Article  Google Scholar 

  • Randall PA, Pardo M, Nunes EJ, López Cruz L, Vemuri VK, Makriyannis A, Baqi Y, Müller CE, Correa M, Salamone JD (2012) Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow task: pharmacological studies and role of individual differences. PLoS One 7(10):e47934

  • Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE (2008) Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 69:87–94

    Article  CAS  PubMed  Google Scholar 

  • Rizvi SJ, Geraci J, Ravindran A, Kennedy SH (2014) Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. J Clin Psychopharmacol 34(6):755–759

    Article  PubMed  Google Scholar 

  • Rosenberg PB, Lanctot KL, Drye LT, Herrmann N, Scherer RW, Bachmann DL, Mintzer JE, ADMET investigators (2013) Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J Clin Psychatry 74:810–816

    Article  CAS  Google Scholar 

  • Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M (2014) The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry 55:1–10

    Article  PubMed  Google Scholar 

  • Rowley HL, Kulkarni R, Gosden J, Brammer R, Hackett D, Heal DJ (2012) Lisdexamfetamine and immediate release d-amfetamine—differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacology 63:1064–1074

    Article  CAS  PubMed  Google Scholar 

  • Salamone JD, Correa M (2012) The mysterious motivational functions of mesolimbic dopamine. Neuron 76:470–485

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K (1991) Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology (Berl) 104:515–521

    Article  CAS  Google Scholar 

  • Salamone JD, Cousins MS, Bucher S (1994) Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res 65:221–229

    Article  CAS  PubMed  Google Scholar 

  • Salamone JD, Arizzi MN, Sandoval MD, Cervone KM, Aberman JE (2002) Dopamine antagonists alter response allocation but do not suppress appetite for food in rats: contrast between the effects of SKF 83566, raclopride, and fenfluramine on a concurrent choice task. Psychopharmacology (Berl) 160:371–380

    Article  CAS  Google Scholar 

  • Salamone JD, Correa M, Mingote S, Weber SM (2003) Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 305:1–8

    Article  CAS  PubMed  Google Scholar 

  • Salamone JD, Correa M, Farrar A, Mingote SM (2007) Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) 191:461–482

    Article  CAS  Google Scholar 

  • Salamone JD, Correa M, Nunes EJ, Randall PA, Pardo M (2012) The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav 97:125–146

    Article  PubMed Central  PubMed  Google Scholar 

  • Salamone JD, Koychev I, Correa M, McGuire P (2015) Neurobiological basis of motivational deficits in psychopathology. Eur Neuropsychopharmacol, 25(8):1225–1238

  • Sevy S, Rosenthal MH, Alvir J, Meyer S, Visweswaraish H, Gunduz-Bruce H, Schooler NR (2005) Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 66:839–843

    Article  CAS  PubMed  Google Scholar 

  • Sommer S, Danysz W, Russ H, Valastro B, Flik G, Hauber W (2014) The dopamine reuptake inhibitor MRZ-9547 increases progressive ratio responding in rats. Int J Neuropsychopharmacol 17:2045–2056

    Article  CAS  PubMed  Google Scholar 

  • Stahl SM (2002) The psychopharmacology of energy and fatigue. J Clin Psychiat 63(1):7–8

    Article  Google Scholar 

  • Stenman E, Lilja A (2013) Increased monoaminergic neurotransmission improves compliance with physical activity recommendations in depressed patients with fatigue. Med Hypotheses 80:47–49

    Article  CAS  PubMed  Google Scholar 

  • Stotz G, Woggon B, Angst J (1999) Psychostimulants in the therapy of treatment-resistant depression. Review of the literature and findings from a retrospective study in 65 depressed patients. Dialogues Clin Neurosci 1(3):165–174

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tadano T, Nakagawasai O, Niijima F, Tan-No K, Kisara K (2000) The effects of traditional tonics on fatigue in mice differ from those of the antidepressant imipramine: a pharmacological and behavioral study. Am J Chin Med 28:97–104

    Article  CAS  PubMed  Google Scholar 

  • Tanno T, Maguire DR, Henson C, France CP (2014) Effects of amphetamine and methylphenidate on delay discounting in rats: interactions with order of delay presentation. Psychopharmacology (Berl) 231:85–89

    Article  CAS  Google Scholar 

  • Treadway MT, Zald DH (2011) Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 35:537–555

    Article  PubMed Central  PubMed  Google Scholar 

  • Treadway MT, Bossaller NA, Shelton RC, Zald DH (2012) Effort-based decision making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol 121(3):553–558

    Article  PubMed Central  PubMed  Google Scholar 

  • Wang JL, Oya S, Parhi AK, Lieberman BP, Ploessl K, Hou C, Kung HF (2010) In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson’s disease. Nucl Med Biol 37:479–486

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wardle MC, Treadway MT, Mayo LM, Zald DH, de Wit H (2011) Amping up effort: effects of d-amphetamine on human effort-based decision-making. J Neurosci 31(46):16597–16602

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L (2009) Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 14:573–585

    PubMed  Google Scholar 

  • Yohn SE, Thompson C, Randall PA, Lee CA, Müller CE, Bagi Y, Correa M, Salamone JD (2015a) The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology (Berl) 232:1313–1323

    Article  CAS  Google Scholar 

  • Yohn SE, Santerre JL, Nunes EJ, Kozak R, Podurgiel SJ, Correa M, Salamone JD (2015b) The role of dopamine D1 receptor transmission in effort-related choice behavior: effects of D1 agonists. Pharmacol, Biochem Behav B135:217–226

    Article  Google Scholar 

  • Yohn SE, Collins SL, Contreras-Mora HM, Errante EL, Rowland MA, Correa M, Salamone JD (2015c). Not all antidepressants are created equal: differential effects of monoamine uptake inhibitors on effort-related choice behavior. Neuropychopharmacology. doi: 10.1038/npp.2015.188. [Epub ahead of print].

  • Young JL (2013) Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo controlled study. Psychiatry Res 207:127–133

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank Emily Errante for her assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John D. Salamone.

Ethics declarations

Funding and disclosure

This research was supported by grants from NIH/NIMH, the University of Connecticut Research Foundation, and the Psychology Department Undergraduate Research Grant program. HC received an NSF Bridge to the Doctorate grant. JS has received grants from, and done consulting work for, Pfizer, Roche, Shire, and Prexa. PHH is an employee of Shire and holds stock and/or stock options in Shire. The authors have nothing to disclose in terms of competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yohn, S.E., Lopez-Cruz, L., Hutson, P.H. et al. Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat. Psychopharmacology 233, 949–960 (2016). https://doi.org/10.1007/s00213-015-4176-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-015-4176-7

Keywords

Navigation